Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma


22 Nov 2020


e-Poster Display Session


Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Oesophageal Cancer;  Gastric Cancer


Jia Wei


Annals of Oncology (2020) 31 (suppl_6): S1287-S1318. 10.1016/annonc/annonc356


J. Wei1, X. Lu2, Q. Liu1, L. Li3, S. Liu4, F. Liu3, Y. Fu3, X. Fan3, J. Yang1, Y. Yang1, Y. Zhao5, W. Guan2, B. Liu1

Author affiliations

  • 1 The Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University, 210000 - Nanjing/CN
  • 2 Department Of General Surgery, Affiliated Drum Tower Hospital to Medical School of Nanjing University, 210000 - Nanjing/CN
  • 3 Department Of Pathology, Affiliated Drum Tower Hospital to Medical School of Nanjing University, 210000 - Nanjing/CN
  • 4 Department Of Radiology, Affiliated Drum Tower Hospital to Medical School of Nanjing University, 210000 - Nanjing/CN
  • 5 Department Of Biostatistics, Nanjing Medical University, 210000 - Nanjing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 196TiP


Concurrent chemoradiotherapy (cCRT) is the standard therapy for locally advanced gastric and GEJ adenocarcinoma with poor prognosis. Programmed cell death receptor-1 (PD-1) inhibitor has been approved to treat ≥3 line gastric and GEJ patients (pts). PACIFIC study demonstrated significant clinical benefits of PD-1 inhibitor in addition to cCRT in locally advanced lung cancer. Sintilimab, a humanized IgG4 monoclonal antibody with high affinity and specificity for PD-1, has shown promising efficacy with an overall response rate of 85% in combination with chemotherapy in gastric cancer in a phase Ib study (NCT02937116). A study was therefore designed to explore the efficacy and safety of perioperative cCRT in combination with sintilimab for pts with locally advanced gastric cancer.

Trial design

This is a prospective, open label, multicentric phase II trial which pts with locally advanced (cT3N2-3 or cT4aN+ or cT4bNany) gastric or GEJ adenocarcinoma will receive preoperative 4 cycles sintilimab in combination with S1, nab-paclitaxel (nab-PTX) and radiotherapy (RT) and post-operative 3 cycles sintilimab with S1 and nab-PTX. Sintilimab will be administered intravenously at flat dose of 200 mg every 3 wks. S1 orally at dose of 40 mg/m2 (bid) and nab-PTX intravenously at 100-120 mg/m2 (d1, d8) will be given for 2 cycles before surgery and 3 cycles after. A weekly nab-PTX (80-100 mg/m2,d1, d8, d15, d22) with concurrent RT (45Gy/1.8Gy*25f) will be given in between 2 cycles of S1 and nab-PTX combination. The primary endpoint is the pathological complete response (pCR), and a Simon optimal two-stage design will be employed to achieve the target at 35% from historical 15%. Secondary endpoints include safety, major pathological response (MPR) (defined by tumor residual ≤10%), R0 resection rate, and overall survival. Collateral translational studies explore the correlation of response with tumor mutational burden or genetic alterations, or biomarkers etc. The trial is now open to enrollment, 13 of planned 34 pts have been enrolled.

Clinical trial identification


Legal entity responsible for the study

Affiliated Drum Tower Hospital to Medical School of Nanjing University.


Innovent Biologics.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.